Listar por autor "Posada Ayala, María"
Mostrando ítems 1-7 de 7
-
Cannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration. Galán Ganga, M.; Rodríguez Cueto, C.; Merchán Rubira, J.; Hernández, F.; Ávila, J.; Posada Ayala, María; Lanciego, J.L.; Luengo, E.; López, M. G.; Rábano, A.; Fernández Ruiz, J.; Lastres Becker, I. (Acta Neuropathological Communications, 2021)
-
Endocannabinoid levels in peripheral blood mononuclear cells of multiple sclerosis patients treated with dimethyl fumarate. Sánchez‑Sanz, Alicia; Posada Ayala, María; Sabín‑Muñoz, Julia; Fernández‑Miranda, Ismael; ; Álvarez‑Lafuente, Roberto; Royuela, Ana; García‑Hernández, Ruth; Rodríguez‑De la Fuente, Ofir; Romero, Julián; García Merino, Antonio; Sánchez‑López, Antonio José; Aladro Benito, Yolanda (Scientific Reports, 2022)
-
Potentiation of amyloid beta phagocytosis and amelioration of synaptic dysfunction upon FAAH deletion in a mouse model of Alzheimer’s disease. Ruiz Pérez, Gonzalo; Ruiz de Martín Esteban, Samuel; Marqués, Sharai; Aparicio, Noelia; Grande Rodríguez, Mª Teresa; Benito Cuesta, Irene; Martínez Relimpio, Ana María; Arnanz, M. Andrea; Tolón, Rosa María; Posada Ayala, María; Cravatt, Benjamin F.; Esteban, José A.; Romero, Julián; Palenzuela Muñoz, Rocío (Journal of Neuroinflammation, 2021)